SEED invests DKK 7.6m in Reapplix

The investment was made through the SEED Capital Denmark II fund and will support further clinical tests on the effect of the company's product. Reapplix has developed a new form of biological plaster to aid recovery for patients suffering from foot ulcers as a consequence of diabetes.

The unquote" team is currently researching this transaction. In-depth deal information for subscribers will follow shortly.

If you have any information regarding this transaction, please contact Viktor Lundvall on +44 20 7004 7476 or viktor.lundvall@incisivemedia.com

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Nordics
• Healthcare
• Early-stage
• Denmark